2011 Warwick Kimmins Science Scholarship Awarded
HALIFAX, NOVA SCOTIA -- (MARKET WIRE) -- 06/14/11 -- Immunovaccine Inc. (TSX VENTURE: IMV), a vaccine development company, has awarded the $1,000 Warwick Kimmins Science Scholarship today to Lauren Clark. Lauren is graduating from Central Kings Rural High School in Nova Scotia and will attend Mount Allison University in September.
"Lauren's winning essay demonstrated creative thinking in terms of discovering new potential treatments for cancer. She showed not only a passion for medical research, but also ideas that would catch any scientist's attention," said Dr. Ryan D'Arcy, a neuroscientist at the National Research Council who judged the scholarship award.
Lauren is motivated to pursue her education, with the goal of advancing cancer research, by her personal experience watching her grandfather's 40-year fight against cancer.
"Due to her outstanding academic record and commitment to her community through music, athletics and community service, we are happy to offer her this scholarship," continued D'Arcy. "We wish her all the best in pursuing her Bachelor of Science degree at Mount Allison."
The scholarship is in memory of Dr. Warwick Kimmins, co-founder of Immunovaccine Inc. Dr. Kimmins was the former Dean of the Faculty of Science at Dalhousie University and was instrumental in bringing Immunovaccine to where it is today.
About Immunovaccine
Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Immunovaccine Inc. Jennifer Ayotte Director of Communications (902) 492-1819 [email protected]
Source: Immunovaccine Inc.
Released June 14, 2011